Different research groups have reported signs of NK cell suppression in cancer patients such as a lower expression of NK cell receptors, e.g., NCRs, NKG2D, DNAM-1, and 2B4 (22, 25, 168–170), the shedding of tumor cell ligands, such as NKp30 and NKG2D (171–174), or the release of blocking NKG2D ligands, such as MICA and ULBP3, via tumor-derived exosomes (175, 176). This evidence concerns the gene CD226 and neoplasm.